Dishman Carbogen Amcis has scheduled its 19th Annual General Meeting for Wednesday, September 30, 2026. The meeting will commence at 3:00 pm via video conferencing or other audio-visual means.

The company issued the intimation to the Bombay Stock Exchange and National Stock Exchange on August 31, 2026. The AGM will be conducted in accordance with circulars from the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

Meeting Details

Shareholders will receive further details regarding attendance and voting procedures in the official notice for the 19th AGM. This document will be dispatched in due course.

The Company Secretary, Shrima Dave, confirmed the date and mode of the meeting in the regulatory filing.

Dishman Carbogen Amcis has published the full transcript of its quarterly earnings conference call. The document provides detailed insights into the company's financial performance and strategic initiatives for the quarter ended June 30, 2026.

The conference call took place on Monday, August 17, 2026, at 5:00 pm IST. In compliance with Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the company filed the transcript with the BSE and NSE. The recording was also made available on the company's official website.

Financial Performance Highlights

During the call, Global CFO Harshil Dalal outlined the financial results for Q1FY27. Revenue from operations stood at INR 6,776 million, representing a 4% decline compared to INR 7,080 million in the corresponding quarter of the previous year. This degrowth was primarily attributed to the postponement of a significant order valued at approximately CHF 10 million to the latter half of the financial year.

EBITDA for the quarter was reported at INR 600 million, down significantly from INR 1,406 million in Q1FY26. The company incurred a loss before tax of INR 512 million and a tax expense of INR 66 million. Finance costs were recorded at INR 370 million, while foreign exchange losses amounted to INR 117.3 million, mainly due to fluctuations between the US dollar and the Swiss franc.

Segment-wise Breakdown

The CDMO segment generated revenue of INR 5,343 million, compared to INR 6,112 million in the prior year quarter. Its EBITDA margin contracted to 6.3% from 17.9%, impacted by deferred revenue and forex losses. Conversely, the Marketable Molecules segment saw revenue rise to INR 1,432 million from INR 968 million. However, its margin normalized to 18.6% from 32% in Q1FY26, driven by a shift in sales mix towards cholesterol products rather than higher-margin analogues.

Operational Updates and Debt Refinancing

Management highlighted several operational milestones. CEO Stephan Fritschi noted that multiple Phase II projects have been transformed into late-phase programs, with over 13 late-phase projects now in the portfolio. A new commercial product from a major pharma client received US FDA approval, adding to the company's commercial portfolio.

Regarding capital structure, CFO Harshil Dalal confirmed that net debt excluding lease liabilities stood at CHF 153.6 million as of June 30, 2026. The company is actively working on refinancing high-cost debt in India through an External Commercial Borrowing (ECB) raised by the promoter entity. Shareholders have approved raising up to CHF 200 million at an all-inclusive interest rate of 4% over a ten-year tenor. Management expects this process to conclude within the next 60-90 days.

Guidance and Outlook

For FY27, management expects single-digit revenue growth for the group, with Indian operations potentially growing by 30-35%. EBITDA margins are expected to be similar to or slightly better than the previous year. For FY28 and FY29, the company anticipates double-digit growth, driven by increased contributions from French and Indian entities, with EBITDA margins targeting 25-26%.